普瑞眼科(301239.SZ)2022年度淨利潤預降75.73%-81.31%
格隆匯1月31日丨普瑞眼科(301239.SZ)公佈，預計2022年度歸屬於上市公司股東的淨利潤1755萬元-2279萬元，同比下降75.73%-81.31%；扣除非經常性損益後的淨利潤1600萬元-2078萬元，同比下降75.74%-81.32%。
業績變動原因如下：(一)主營業務收入下降的影響。2022年度，全國各地疫情反覆持續，各地疫情防控政策對社會經濟活動產生很大影響，第四季度疫情防控又進入新階段，各地陸續迎來感染高峯，對直接面對個體患者開展診療業務的眼科行業造成不利影響，尤其是二季度和四季度的衝擊較大。公司在昆明、成都、武漢、重慶等城市的成熟醫院收入和利潤較上年同期增速放緩；上海、蘭州、烏魯木齊等城市的醫院因當地疫情嚴峻複雜，經歷了長時間的停診狀態，使得營業收入出現同比下滑，而蘭州和烏魯木齊作為公司的利潤貢獻中心，本年度對整體利潤貢獻相應下降；瀋陽、天津等城市的培育期醫院收入增長不及預期，減虧數額有限。
(二)成本、費用上升的影響。公司登陸資本市場後，新建醫院投資擴張計劃加速推進，2022年自建的5家眼科專科醫院相繼開診，正式開診後產生的各類資產折舊攤銷、人工成本和期間費用等剛性開支對成本、費用增長影響較大；同時，為了繼續在全國各大中心城市實施“全國連鎖化＋同城一體化”的戰略，確保2023年醫院擴張佈局計劃的順利執行，公司還有多家眼科專科醫院正在籌備過程中，大量前期投入也對本年利潤產生影響。
隨着公司規模加速擴張，需要持續加強總部和區域總部建設，本年度公司已完成組織架構的調整和優化，完善各部門職能，通過引入大量管理人才強化對全國經營佈局的運營、維護和服務支持，使得人工薪酬支出上升，2022年度管理費用和銷售費用佔營業收入的比例較2021年度均有所上升，導致公司利潤出現下滑。
(三)非經常性損益的影響。報吿期內，非經常性損益對歸屬於上市公司股東的淨利潤的影響金額約155萬元-201萬元，主要系政府補助和捐贈支出所致。
2022年度，公司積極響應國家抗疫號召，踐行企業社會責任，同時緊緊圍繞公司既定的戰略目標，積極開拓進取，提升管理水平和效率，努力實現平穩有序運營，切實維護全體股東利益。隨着疫情防控全面放開，社會經濟逐步恢復正常並釋放活力，眼科醫療服務行業將重回正常發展的軌道，公司前期佈局投入和降本提效的成效將在未來逐步顯現。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
